© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology
Margolimab Generates Hope for Patients With Myelodysplastic Syndromes, AML
July 08, 2020
In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the safety and efficacy findings of margolimab as treatment of patients with TP53-positive AML and high-risk MDS.
FDA Approves Decitabine Plus Cedazuridine for MDS With Multiple Indications
July 07, 2020
FDA has granted approval to the combination regimen decitabine and cedazuridine as treatment of adult patients with myelodysplastic syndromes under multiple indications.
Disparities Seen in Hematologic Cancer Incidence and Survival for Hispanic Patients in Texas
June 22, 2020
“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."
Ropeginterferon Provides Improved Hematocrit Control Over Phlebotomy Alone in Low-Risk PV
June 14, 2020
"This interim analysis demonstrated ropeginterferon in low-risk patients is more efficacious in keeping the hematocrit [at target levels]. In addition, we get a better quality of life and the target was reached with a reduction of phlebotomy needs."
Eprenetapopt Plus Azacitidine Yields Promising Responses in High-Risk MDS/AML
June 14, 2020
"The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat [patients with] TP53-mutant MDS and AML, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities,."
Expert Discusses Novel Treatment Approach for TP53-Mutant MDS and AML
June 11, 2020
In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discussed the novel agent, APR-246, and its significance for use in the patients with myelodysplastic syndrome and acute myeloid leukemia
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma
May 30, 2020
“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."
Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
May 29, 2020
"The totality of data from the two trials presented at ASCO suggests that zanubrutinib may be a preferred treatment option for patients with WM, regardless of whether they have received prior treatment."
Encouraging Preliminary Findings Demonstrated for Belantamab Mafodotin Combo in R/R Multiple Myeloma
May 29, 2020
“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified. Clinical response looks promising."
Improved Responses Achieved for R/R Multiple Myeloma With Selinexor Combo
May 29, 2020
Selinexor in combination with bortezomib and dexamethasone resulted in improvements in responses and outcomes compared with bortezomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to findings from the phase 3 BOSTON trial from the 2020 ASCO Virtual Scientific Program.